Get the Stockscreener App
1.235
1.98%
-0.025
Biodesix Inc stock is currently priced at $1.235, with a 24-hour trading volume of 13,931.
It has seen a -1.98% decreased in the last 24 hours and a -14.83% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.25 pivot point. If it approaches the $1.22 support level, significant changes may occur.
Previous Close:
$1.26
Open:
$1.24
24h Volume:
13,931
Market Cap:
$141.64M
Revenue:
$49.09M
Net Income/Loss:
$-52.15M
P/E Ratio:
-1.1227
EPS:
-1.1
Net Cash Flow:
$-45.93M
1W Performance:
-1.20%
1M Performance:
-14.83%
6M Performance:
-15.99%
1Y Performance:
-31.39%
1D Range:
$1.21
$1.24
52W Range:
$1.03
$2.21
Biodesix Inc Stock (BDSX) Company Profile
Name
Biodesix Inc
Sector
Industry
Phone
303-417-0500
Address
2970 Wilderness Place, Suite 100, Boulder
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-23-20 | Initiated | BTIG Research | Buy |
| Nov-23-20 | Initiated | Canaccord Genuity | Buy |
| Nov-23-20 | Initiated | Morgan Stanley | Overweight |
| Nov-23-20 | Initiated | William Blair | Outperform |
Biodesix Inc Stock (BDSX) Latest News
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
Zacks Investment Research
Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now
Zacks Investment Research
Masimo (MASI) Gains Nearly 18% YTD: What's Driving the Rally?
Zacks Investment Research
S&P 500 Gains Over 1%; GCT Semiconductor Shares Spike Higher
Benzinga
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Gold Surges Over 1%; Biodesix Shares Plummet
Benzinga
Biodesix Inc Stock (BDSX) Financials Data
Biodesix Inc (BDSX) Revenue 2024
BDSX reported a revenue (TTM) of $49.09 million for the quarter ending December 31, 2023, a +28.46% rise year-over-year.
Biodesix Inc (BDSX) Net Income 2024
BDSX net income (TTM) was -$52.15 million for the quarter ending December 31, 2023, a +20.32% increase year-over-year.
Biodesix Inc (BDSX) Cash Flow 2024
BDSX recorded a free cash flow (TTM) of -$45.93 million for the quarter ending December 31, 2023, a +5.31% increase year-over-year.
Biodesix Inc (BDSX) Earnings per Share 2024
BDSX earnings per share (TTM) was -$0.65 for the quarter ending December 31, 2023, a +59.12% growth year-over-year.
About Biodesix Inc
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests provide physicians with timely results to facilitate treatment decisions. It also offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as develops and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated 2005 and is headquartered in Boulder, Colorado.
0.03%
Cap:
|
Volume (24h):